Efficacy of tenofovir as first-line antiviral therapy in chronic Hepatitis B infection.

Cite this:
[1]
J. S. Zainah Saat, “Efficacy of tenofovir as first-line antiviral therapy in chronic Hepatitis B infection”., ijmhs, vol. 5, no. 2, pp. 73–78, Apr. 2015.
© 2022 Interactive Protocols
RIGHTS & PERMISSIONS
Article Views
240
Altmetric
1
Citations
-
LEARN ABOUT THESE METRICS
   PDF  

Abstract

To date, various antiviral therapy options are available in treatment of chronic hepatitis B (CHB). Choosing the right drug according to patients’ profile is utmost crucial for optimal response, recovery and prevention of drug resistance. Tenofovir (TDF) is an approved first-line drug treatment for CHB. Several studies have reported on the safety and efficaciousness of TDF in treating CHB patients and achieving improvement. This narrative review article aimed to compile study evidences that highlighted the effectiveness of TDF as antiviral therapy in CHB patients. From the analysis done, it can be summarized that patients who have been undergoing TDF monotherapy or switched to TDF after other antiviral therapy had profound HBV DNA suppression level, no resistance detected and improved health condition. Based on this, TDF is strongly recommended to be continued as first-line treatment for CHB patients.

KEYWORDS:

 Special Issue

Article Metrics Graph

Chart Graph | Range Graph

Content

Section

Source

License

All paper submissions must carry the following duly signed by all the authors:
“I certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.”